Recevez les dernières nouvelles sur l'action Gyre Therapeutics avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de GYRE

Dernières nouvelles pour

GYRE THERAPEUTICS INC

Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gyre Therapeutics Inc

Press Releases

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

News

Financing

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Health Care

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Earnings

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Management

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

GYRE

Absci

Akebia Therapeutics

Astria Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kura Oncology

Lexeo Therapeutics

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Myriad Genetics

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

RAPT Therapeutics

Replimune Group

Regenxbio

Savara

Tyra Biosciences

UroGen Pharma

Vir Biotechnology

Jefferies

HC Wainwright & Co.

Comments

Gyre Therapeutics Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL